Stocktoria
NeuroPace Inc NPCE
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2021-04-22
NeuroPace Inc financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $100.0M | $79.9M | $65.4M | $45.5M | $45.2M | $41.1M |
| Gross profit | $77.2M | $59.1M | $48.1M | $32.5M | $33.4M | $30.3M |
| R&D expense | $27.9M | $23.7M | $20.8M | $21.9M | $18.2M | $15.7M |
| SG&A expense | — | $57.1M | $54.5M | $51.3M | $39.0M | $27.6M |
| Operating income | -$16.3M | -$21.7M | -$27.2M | -$40.8M | -$23.7M | -$13.1M |
| Interest expense | — | — | $8.5M | $7.5M | $7.4M | $11.5M |
| Income tax | $0 | — | — | — | — | — |
| Net income | -$21.5M | -$27.1M | -$33.0M | -$47.1M | -$36.1M | -$24.3M |
| EPS (diluted) | $-0.66 | $-0.93 | $-1.27 | $-1.91 | $-2.17 | $-117.85 |
| Operating cash flow | -$11.0M | -$17.9M | -$19.7M | -$36.9M | -$24.6M | -$21.6M |
| Free cash flow | -$11.3M | -$18.3M | -$19.9M | -$37.5M | -$25.0M | -$21.7M |
| Cash & equivalents | $21.7M | $13.4M | $18.1M | $6.6M | $19.2M | $26.4M |
| Inventory | $14.9M | $13.4M | $11.2M | $9.7M | $7.8M | $6.9M |
| Total assets | $105.6M | $94.6M | $107.7M | $114.1M | $133.6M | $56.0M |
| Total liabilities | $86.5M | $86.6M | $87.0M | $79.3M | $60.1M | $62.4M |
| Shareholders' equity | $19.0M | $8.0M | $20.7M | $34.8M | $73.5M | -$147.8M |
Growth · year-over-year · Revenue CAGR 19.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +25.1% | +22.1% | +43.7% | +0.7% | +9.8% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.